ReviewFrontiers in immunology2026
Mitochondrial reprogramming in cervical cancer: crosstalk with tumor immunity, HPV oncogenic signaling, and therapeutic resistance.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a major malignancy in women worldwide despite advances in human papillomavirus (HPV) vaccination, screening, and multimodal treatment. Persistent high-risk HPV infection is the principal driver of cervical carcinogenesis, yet viral oncogenesis alone cannot fully explain tumor progression, immune escape, and therapeutic failure. Increasing evidence suggests that mitochondrial reprogramming is a critical adaptive process that links HPV-driven transformation to metabolic plasticity, tumor immunity, and resistance to therapy. Beyond their canonical role in ATP production, mitochondria regulate redox homeostasis, mitochondrial dynamics, mitophagy, apoptotic priming, and mitochondria-derived danger signaling, thereby shaping both tumor-cell fitness and the surrounding immune microenvironment. In cervical cancer, HPV-associated oncogenic signaling promotes metabolic and mitochondrial remodeling, while downstream mitochondrial processes help sustain malignant growth, buffer oxidative and therapeutic stress, and influence immune responsiveness. Emerging studies further indicate that mitochondrial stress signals, particularly mitochondrial DNA-mediated innate immune activation, may connect tumor metabolism with anti-tumor immunity and immunotherapeutic sensitivity. At the same time, mitochondrial respiration, redox adaptation, and quality-control mechanisms contribute to chemoresistance and broader treatment tolerance. In this review, we summarize current evidence on how HPV oncogenic signaling reshapes mitochondrial biology in cervical cancer and discuss how mitochondrial reprogramming influences tumor immunity, immune evasion, and therapeutic resistance. We also highlight emerging mitochondria-targeted strategies and propose future directions for mechanistic and translational research. Together, these insights position mitochondrial reprogramming as both a conceptual framework and a potential therapeutic vulnerability in cervical cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.